Headquarterd in San Feancisco Bay Area, Acepodia was founded in 2017 by Dr, Patrick Y, Yang, former EVP of Juno Therapeutics,Roche and Genentech, and by Dr. Sonny Hsiao, UC Berkeley Cell Biologist and inventor of Acepodia 's core technology. Acepodia is a privately held biotechnology company focused on developing novel, t argeted, allogeneic cell therapies to treat c ancers.

Founded in 1965, Adimmune Corporation is the only influenza vaccine manufacturer with both EU GMP and US FDA certificates in Taiwan.
Our major products include Trivalent Influenza Vaccine, Quadrivalent Influenza Vaccine, Influenza A (H1N1) Virus Monovalent Vaccine, Japanese Encephalitis Vaccine (JEV), Tetanus Toxoid, and purified Tuberculin.

"Advagene Biopharma Co., Ltd. is a biopharmaceutical company that aims to develop mucosal immunotherapy, committed to providing human beings around the world the biopharmaceutical development for better epidemic prevention and treatment.
Advagene's core technology: detoxified LT adjuvant (LTh (αK)) platform, can regulate not only humoral but also mucosal immunity and enhance the production of mucosal immunoglobulin A (IgA), which can fortify the efficacy of vaccines and can change the transmission route; such development has high medical potential. Advagene has applied this into the development of nasal influenza vaccine (LT-Flu), respiratory allergy treatment (LT-Allergy), COVID-19 immunotherapy, nasal COVID-19 vaccine and other vaccines, among which LT-Flu nasal flu vaccine phase II clinical trial has been completed at the end of the first season in 2019. LT-Allergy's phase I/II clinical trial is completed and administered in 2020."

AnnJi Pharmaceutical, a pioneering biopharmaceutical company, is dedicated to the discovery and development of novel small molecule drugs (NCEs) targeting neurological, dermatological, and inflammatory diseases. The company's mission centers on addressing areas of high medical need, particularly rare and underserved conditions that have long been overlooked.

At AnnJi, we are driven by the pursuit of first-in-class therapies. By exploring and validating novel mechanisms of action, we aim to deliver treatments that go beyond symptom management-offering real change in areas where few or no options exist.

Our team brings deep expertise in translational medicine and drug development, allowing us to seamlessly bridge the gap between early-stage discovery and clinical application. To support our research, we operate an in-house preclinical lab that enables efficient execution of in vitro and in vivo pharmacology, pharmacokinetics, and drug metabolism studies.

This integrated approach not only accelerates development timelines but also strengthens our intellectual property strategy and product lifecycle planning- positioning AnnJi at the forefront of therapeutic innovation for patients who need it most.

AM Biotech, founded by Dr. Richard Shieh, specializes in stem cell and exosome technologies. Utilizing its proprietary "Bio-Pulsed" technology, the company produces high-purity, targeted exosomes for for applications in biopharmaceuticals, scalp care, and medical aesthetics. AM Biotech operates a GMP-compliant R&D and manufacturing laboratory and collaborates extensively with medical institutions and academic organizations. Through ongoing clinical and efficacy studies, the company is committed to driving innovation in regenerative medicine and health and beauty technologies.

Astra Zeneca (LEs/stO Nasdag AZN) is a global science-led biopharmaceutical company that focuises on the discovery development amd commercialisation of ptescription medicines m Oncology Rare Diseases amd Bio Pharmaceuticals。 including Cardiovascula Renal & Metabolism and Respiratory &Immunology Based in Cambridge UK AstaZeneca operates in over 10coumtries and its mnovative medicimnes are used by millions of patients worldwide

BeOne Medicines is a global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. With a broad portfolio, we are expediting development of our diverse pipeline of novel therapeutics through our internal capabilities and collaborations. We are committed to radically improving access to medicines for far more patients who need them. Our growing global team of more than 10,000 colleagues spans five continents. To learn more about BeOne Medicines, please visit www.beonemedicines.com and follow us on LinkedIn and Facebook.

Founded in 2015, BioGate adheres to the core concept of precision medicine, "Right Target, Right Drug, Right Patient, Right Time", and is committed to developing first-in-class antibody drugs in oncology. BioGate provides patients with highly specific and effective treatment through novel mechanism of action and innovative drug design.

BioGate efficiently screens suitable therapeutic targets and produces highly promising antibody drugs through a novel antibody technology platform. Combined with advanced biomarker technology, BioGate provides precise therapies for cancer patients with disease progression, so as to enhance treatment outcomes and improve patients' quality of life.